HDAC9 and inflammatory bowel disease: It has been demonstrated, among other findings, that butyrate (SCFA) acts synergistically with βOHB, reducing intestinal inflammatory conditions in children with inflammatory bowel disease (IBD) and inhibiting histone deacetylase (HDAC), reducing inflammatory cytokine production and increasing H3 histone acetylation in macrophages.